Press Releases Abliva AB

Equities

ABLI

SE0002575340

Delayed Nasdaq Stockholm Other stock markets 14:53:04 13/05/2024 BST			5-day change	1st Jan Change
0.1908 ^SEK	+0.42%		+8.03%	-21.06%

02-23	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024	01:30pm	AQ
Amended number of shares and votes in Abliva AB (publ)	04-30	AQ
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue	04-25	AQ
Abliva AB Publishes 2023 Annual Report	04-24	AQ
Notice of Annual General Meeting of Abliva AB (publ)	04-22	AQ
Abliva publishes rights issue outcome	04-19	AQ
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	04-08	AQ
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	03-27	AQ
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	03-26	AQ
BioStock: Abliva's CEO comments on the proposed capital raise	02-29	AQ
Abliva AB Year-End Report January – December 2023	02-23	AQ
Notice of Extraordinary General Meeting of Abliva AB (publ)	02-22	AQ
The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study	02-22	AQ
BioStock: Abliva reaches enrollment goal	12-21	AQ
Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	12-20	AQ
BioStock: Abliva's CEO: "Orphan drug designation is great validation"	12-15	AQ
Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354	12-14	AQ
Abliva AB Interim Report January – September 2023	11-17	AQ
BioStock: Abliva signs global license deal for NeuroSTAT	11-16	AQ
Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury	11-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Abliva AB

Equities

ABLI

SE0002575340

Press Releases

Filters